thyroxine has been researched along with Neuroectodermal Tumors, Primitive in 1 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Neuroectodermal Tumors, Primitive: A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059)
| Excerpt | Relevance | Reference |
|---|---|---|
| "From Jan 1998 to Feb 2001, a total of 37 euthyroid children scheduled for CSI for medulloblastoma/primitive neuroectodermal tumor underwent thyroid ultrasound and free triiodothyronine (FT3), free thyroxine (FT4), and TSH evaluation at the beginning and end of CSI." | 3.74 | Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. ( Biassoni, V; Bombardieri, E; Collini, P; Fossati-Bellani, F; Gandola, L; Marchianò, A; Massimino, M; Pallotti, F; Pignoli, E; Seregni, E; Serra, A; Spreafico, F; Terenziani, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Massimino, M | 1 |
| Gandola, L | 1 |
| Collini, P | 1 |
| Seregni, E | 1 |
| Marchianò, A | 1 |
| Serra, A | 1 |
| Pignoli, E | 1 |
| Spreafico, F | 1 |
| Pallotti, F | 1 |
| Terenziani, M | 1 |
| Biassoni, V | 1 |
| Bombardieri, E | 1 |
| Fossati-Bellani, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protection From Iatrogenic Hypothyroidism Patients With MBL and Pediatric Patients With HL and Non-HL Needing Radiotherapy on Thyroid Site[NCT05316922] | Phase 3 | 68 participants (Anticipated) | Interventional | 2021-12-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for thyroxine and Neuroectodermal Tumors, Primitive
| Article | Year |
|---|---|
Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor.
Topics: Adolescent; Adult; Biomarkers; Brain Neoplasms; Child; Child, Preschool; Cranial Irradiation; Diseas | 2007 |